The combination of dual PI3K/mTOR inhibition and temozolomide has been demonstrated to synergistically inhibit tumor growth and reduce GH/PRL levels in pituitary adenoma cell lines and in a mouse GH3 tumor model [86]. The gene discussed is PIK3CA; the disease is neoplasm.